April 12, 2019 02:54 PM EDTUpdated May 30, 11:52 AM
R&D

J&J nabs ac­cel­er­at­ed FDA OK for one of their top late-stage drugs

John Carroll

Editor & Founder

Score one new po­ten­tial block­buster OK for J&J.

The FDA of­fered a quick stamp of ap­proval for their sol­id tu­mor drug erdafi­tinib Fri­day af­ter­noon, al­low­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

FDA's Pe­ter Marks re­signs, say­ing he won't ac­cept Kennedy's 'mis­in­for­ma­tion and lies'

Blue­bird gets new M&A bid, seek­ing to top pri­vate eq­ui­ty of­fer

Small biotech joins list of health com­pa­nies tak­ing a trip to Trump's Mar-a-La­go

‘Peo­ple will die’: End of NIH grants guts work be­tween aca­d­e­mics and com­pa­nies to counter next pan­dem­ic

No­vo Nordisk pays $200M up­front for Chi­na-based biotech’s triple-G obe­si­ty shot

FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B

A service from the Financial Times